VA Establishes Partnership to Deliver Personalized Cancer Care to Veterans
Following the findings of recent cancer studies, the Department of Veterans Affairs (VA) will look to genetic evaluations to provide better cancer care to veterans. A new initiative between the VA, Department of Defense (DoD), and the National Cancer Institute (NCI) will combine their forces to create a new, targeted-care program codenamed APOLLO.
The Applied Proteogenomics Organizational Learning and Outcomes consortium (APOLLO) is an offshoot of the existing Cancer Moonshot program. Starting with lung cancer patients cared for at DoD and VA medical centers, APOLLO will identify and catalog genetic discoveries in DoD patients and add them to a central database.
Both the VA and NCI will share progress and results in this database, which will eventually allow a better understanding of cancer types and individual genetic differences. Eventually, the APOLLO project hopes to create a new standard of cancer care and treatment with proteogenomics, a study of genes and the effects those genes may have later.
Genetic involvement in cancers of all types has become a new focus for cancer research across the globe. Doctors are looking to develop new types of chemotherapy drugs and treatment methods that target specific genetic combinations. This will help reduce harm to healthy tissue. Genetic research and alteration might even be able to reduce the risk of cancer in people with a genetic disposition.
Some Cancers May Qualify Veterans for Disability Benefits
As research continues on environmental exposures during certain conflict eras, the VA has been able to identify the cause of many different types of service-related cancer. If you developed cancer after service, you might qualify for veterans’ disability benefits.
Contact the Disability Help Group at 800-800-2009 to schedule a free consultation with one of our disability advocates today.